These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis. Andrisani G; Gremese E; Guidi L; Papa A; Marzo M; Felice C; Pugliese D; Armuzzi A Reumatismo; 2013 May; 65(2):75-8. PubMed ID: 23877411 [TBL] [Abstract][Full Text] [Related]
7. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Armuzzi A; Pugliese D; Nardone OM; Guidi L Drug Des Devel Ther; 2013; 7():289-96. PubMed ID: 23630414 [TBL] [Abstract][Full Text] [Related]
8. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881 [TBL] [Abstract][Full Text] [Related]
9. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis. Burness CB; Keating GM BioDrugs; 2013 Jun; 27(3):247-62. PubMed ID: 23580096 [TBL] [Abstract][Full Text] [Related]
10. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965 [TBL] [Abstract][Full Text] [Related]
11. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821 [TBL] [Abstract][Full Text] [Related]
12. Adalimumab: A 'Maillon Faible' in the Treatment of Ulcerative Colitis? Roblin X; Paul S J Crohns Colitis; 2024 Mar; 18(3):337-338. PubMed ID: 37847799 [No Abstract] [Full Text] [Related]
13. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530 [TBL] [Abstract][Full Text] [Related]
15. Active ulcerative colitis diagnosed by (18)F-FDG PET/CT in an anti-TNF alpha treated patient with no visible luminal lesions on colonoscopy. Parbo P; Stribolt K; Rittig CS; Gormsen LC Int J Colorectal Dis; 2014 May; 29(5):643-4. PubMed ID: 24531694 [No Abstract] [Full Text] [Related]
16. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [TBL] [Abstract][Full Text] [Related]
17. Vedolizumab for the treatment of ulcerative colitis. Stallmach A; Schmidt C; Teich N Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993 [TBL] [Abstract][Full Text] [Related]
18. Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis. Kim JH; Cheon JH Gut Liver; 2016 Mar; 10(2):162-3. PubMed ID: 26934881 [No Abstract] [Full Text] [Related]
19. [Golimumab Therapy in Ulcerative Colitis]. Moon W Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481 [TBL] [Abstract][Full Text] [Related]
20. Clinical experience with adalimumab in anti-TNF-naïve patients with ulcerative colitis. Busquets D; Aldeguer X J Crohns Colitis; 2013 Jun; 7(5):e195. PubMed ID: 23219261 [No Abstract] [Full Text] [Related] [Next] [New Search]